HER2陽性乳がん治療の世界市場:化学療法、標的治療、ホルモン療法...市場調査レポートについてご紹介

【英文タイトル】Global HER-2 Positive Breast Cancer Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Disease Overview
06.1 Understanding the Disease
06.2 Pathophysiology
06.3 Epidemiology
06.4 Diagnosis
06.4.1 Immunohistochemistry
06.4.2 FISH
06.4.3 SPoT-Light HER2 CISH Test (Subtraction Probe Technology Chromogenic In Situ Hybridization)
06.4.4 Inform HER2 Dual ISH Test (Inform Dual In Situ Hybridization)
06.5 Management
06.5.1 Surgery
06.5.2 Radiotherapy
06.5.3 Chemotherapy
06.5.4 Targeted Therapy
06.5.5 Hormonal Therapy
06.6 Economic Burden

07.Pipeline Analysis

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 HER-2 Positive Breast Cancer Market in US
08.3.1 Market Size and Forecast
08.4 HER-2 Positive Breast Cancer Market in EU
08.4.1 Market Size and Forecast
08.5 Five Forces Analysis

09.Market Segmentation by Type of Therapy
09.1 Chemotherapy
09.1.1 Alkylating agents
09.1.2 Antimetabolites
09.1.3 Cytotoxic antibiotics
09.1.4 Taxanes
09.2 Targeted Therapy
09.3 Hormone Therapy

10.Market Segmentation by Molecule Type
10.1 Biologics
10.2 Small Molecules

11.Market Segmentation by Route of Administration
11.1 Oral
11.2 Parenteral

12.Geographical Segmentation

13.Buying Criteria

14.Market Growth Drivers

15.Drivers and their Impact

16.Market Challenges

17.Impact of Drivers and Challenges

18.Market Trends

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Competitive Assessment of the Top Drugs
20.2.2 Celgene
20.2.3 F. Hoffmann-La Roche
20.2.4 GlaxoSmithKline
20.2.5 Novartis
20.2.6 Sanofi
20.3 SWOT Analysis of the Targeted Therapies
20.3.1 Herceptin
20.3.2 Kadcyla
20.3.3 Perjeta
20.3.4 Tykerb
20.4 Other Prominent Vendors

21.Key Vendor Analysis
21.1 Celgene
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Strategy
21.1.4 Business Segmentation by Revenue
21.1.5 Sales by Geography
21.1.6 Key Information
21.1.7 SWOT Analysis
21.2 F. Hoffmann-La Roche
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Business Strategy
21.2.7 Key Information
21.2.8 SWOT Analysis
21.3 GlaxoSmithKline
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Pipeline Products
21.3.7 Business Strategy
21.3.8 Key Information
21.3.9 SWOT Analysis
21.4 Novartis
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis
21.5 Sanofi
21.5.1 Key Facts
21.5.2 Business Description
21.5.3 Business Segmentation
21.5.4 Revenue by Business Segmentation
21.5.5 Revenue Comparison 2012 and 2013
21.5.6 Sales by Geography
21.5.7 Business Strategy
21.5.8 Key Developments
21.5.9 SWOT Analysis

22.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Executive Summary of Global HER-2 Positive Breast Cancer Market 2015-2019
Exhibit 3: Pathophysiology: HER-2 Positive Breast Cancer
Exhibit 4: Prevalence Data of HER-2 Positive Breast Cancer in the US, 2014
Exhibit 5: Diagnosis of HER-2 Positive Breast Cancer: IHC
Exhibit 6: Diagnosis of HER-2 Positive Breast Cancer: FISH
Exhibit 7: Management of HER-2 Positive Breast Cancer
Exhibit 8: ASCO Treatment Guidelines: HER-2 Positive Breast Cancer
Exhibit 9: Snapshot of Economic Burden of the HER-2 Positive Breast Cancer Market in US
Exhibit 10: Pipeline Snapshot: Combination Therapies
Exhibit 11: Pipeline Snapshot: Therapeutic Vaccines
Exhibit 12: Snapshot of Global HER-2 Positive Breast Cancer Market 2014
Exhibit 13: Global HER-2 Positive Breast Cancer Market 2014-2019 (US$ million)
Exhibit 14: Drivers and Challenges of the Global HER-2 Positive Breast Cancer Market
Exhibit 15: HER-2 Positive Breast Cancer Market in US 2014-2019 (US$ million)
Exhibit 16: HER-2 Positive Breast Cancer Market in EU 2014-2019 (US$ million)
Exhibit 17: Global HER-2 Positive Breast Cancer Market Segmentation by Type of Therapy
Exhibit 18: Global HER-2 Positive Breast Cancer Market Segmentation by Type of Therapy 2014
Exhibit 19: Global HER-2 Positive Breast Cancer Market Segmentation by Molecule Type
Exhibit 20: Global HER-2 Positive Breast Cancer Market Segmentation by Molecule Type 2014
Exhibit 21: Global HER-2 Positive Breast Cancer Market Segmentation by Route of Administration
Exhibit 22: Global HER-2 Positive Breast Cancer Market Segmentation by Route of Administration 2014
Exhibit 23: Geographical Segmentation of Global HER-2 Positive Breast Cancer Market 2014
Exhibit 24: 5-Year Survival Rate by Stage of Diagnosis (SEER analysis for 2004-2010)
Exhibit 25: Revenue Comparison of Top Drugs for HER-2 Positive Breast Cancer in 2013 (US$ million)
Exhibit 26: Product Portfolio: Celgene
Exhibit 27: YoY Growth Rate and Global Revenue of Abraxane 2010-2013 (US$ million)
Exhibit 28: Product Portfolio: F. Hoffmann-La Roche
Exhibit 29: YoY Growth Rate and Revenue of Herceptin 2010-2013 (US$ million)
Exhibit 30: Revenue of Perjeta for 2012-2013 (US$ million)
Exhibit 31: YoY Growth Rate and Revenue of Xeloda 2010-2013 (US$ million)
Exhibit 32: Product Portfolio: GlaxoSmithKline
Exhibit 33: YoY Growth Rate and Revenue of Tykerb 2010-2013 (US$ million)
Exhibit 34: Product Portfolio: Novartis
Exhibit 35: YoY Growth Rate and Revenue of Femara 2010-2013 (US$ million)
Exhibit 36: Product Portfolio: Sanofi
Exhibit 37: YoY Growth Rate and Global Revenue of Taxotere 2010-2013 (US$ million)
Exhibit 38: Herceptin: SWOT Analysis
Exhibit 39: Kadcyla: SWOT Analysis
Exhibit 40: Perjeta: SWOT Analysis
Exhibit 41: Tykerb: SWOT Analysis
Exhibit 42: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 43: Celgene: Sales by Geography 2013
Exhibit 44: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 45: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 46: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 47: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 48: GlaxoSmithKline: Business Segmentation 2013
Exhibit 49: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 50: GlaxoSmithKline: Sales by Geography 2013
Exhibit 51: GlaxoSmithKline: Pipeline Products 2013
Exhibit 52: Novartis AG: Business Segmentation
Exhibit 53: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 54: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 55: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 56: Sanofi SA: Business Segmentation
Exhibit 57: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 58: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 59: Sanofi SA: Sales Revenue by Geographical Segmentation 2013


【レポート販売概要】

■ タイトル:HER2陽性乳がん治療の世界市場:化学療法、標的治療、ホルモン療法
■ 英文:Global HER-2 Positive Breast Cancer Market 2015-2019
■ 発行日:2015年3月4日
■ 調査会社:Technavio
■ 商品コード:IRTNTR5462
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。